Boehringer plans 2027 survodutide submission after positive heart safety trial

Boehringer Ingelheim presented results from the Synchronize-CVOT study at the American Heart Association Scientific Sessions, showing that survodutide achieved a hazard ratio of 0.89 in comparing major adverse cardiovascular events against placebo among 5,530 adult participants. The dual glucagon and GLP-1 receptor agonist also met secondary endpoints regarding cardiometabolic health markers.

While the drug demonstrated a meaningful weight loss of up to 13.7% at Week 72, it faces intense competition from established blockbusters like Eli Lilly's Zepbound. Furthermore, the trial noted higher discontinuation rates due to gastrointestinal adverse events, ranging between 19.3% and 20.8% across treatment arms, though company representatives express confidence that flexible dosing adjustments in future practice will mitigate this issue.

Boehringer is pursuing a dual-path regulatory strategy, aiming to seek approval for both obesity and metabolic dysfunction-associated steatohepatitis (MASH), with the initial weight loss application targeted for submission next year.